About Arielle Medford, MD
Dr. Medford obtained her medical degree from the Johns Hopkins University School of Medicine. She completed internal medicine residency at the Massachusetts General Hospital (MGH), where she won several awards including the Harvard Medical School Resident Teaching Award and the MGH Humanism in Medicine Award. She subsequently returned to the MGH to serve as Chief Resident. She completed her medical oncology fellowship at the Dana Farber Cancer Institute/Mass General Cancer Center, where she also became a clinical post-doctoral fellow at the Broad Institute of Harvard & MIT. Her research focuses primarily on the clinical-translational applications of circulating tumor DNA in early and advanced breast cancer, and how these tools can be used to lead to more personalized care for individual patients living with breast cancer. Dr. Medford is a recipient of the Young Investigator Award from the ASCO Conquer Cancer Foundation.
Clinical Interests:
- Breast Cancer
- Circulating Tumor DNA
- Genomics
- Molecular Residual Disease
Treats:
- Adult
Languages:
- Spanish
Locations
Mass General Cancer Center
55 Fruit St.
Boston, MA 02114
Phone: 617-726-5130
Phone: 877-726-5130
Mass General Cancer Center in Danvers
102 Endicott St.
Danvers, MA 01923
Phone: 978-882-6060
Medical Education
- MD, John Hopkins University School of Medicine
- Residency, Massachusetts General Hospital
- Fellowship, Brigham and Women's Hospital
- Fellowship, Dana Farber Cancer Institute
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Internal Medicine, American Board of Internal Medicine
- Medical Oncology, American Board of Internal Medicine
Publications
-
Medford, A. J., Dubash, T. D., Juric, D., Spring, L., Niemierko, A., Vidula, N., Peppercorn, J., Isakoff, S., Reeves, B. A., LiCausi, J. A., Wesley, B., Malvarosa, G., Yuen, M., Wittner, B. S., Lawrence, M. S., Iafrate, A. J., Ellisen, L., Moy, B., Toner, M., Maheswaran, S., Haber, D.A., Bardia, A. (2019). Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. NPJ Precision Oncology, 3, 18.
Medford, A. J., Oshry, L., Boyraz, B., Kiedrowski, L., Menshikova, S., Butusova, A., Dai, C. S., Gogakos, T., Keenan, J. C., Occhiogrosso, R. H., Ryan, P., Lennerz, J. K., Spring, L. M., Moy, B., Ellisen, L. W., & Bardia, A. (2023). TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis. Therapeutic Advances in Medical Oncology, 15, 17588359231152844.
Medford, A. J., Denault, E. N., Moy, B., Parsons, H. A., & Bardia, A. (2023). Circulating Tumor DNA in Breast Cancer: Current and Future Applications. Clinical Breast Cancer.
Medford, A. J., Moy, B., Spring, L. M., Hurvitz, S. A., Turner, N. C., Bardia, A. (2023). Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception. Clinical Cancer Research.